Name | vilazodone |
---|---|
Synonyms |
5-{4-[4-(5-Cyano-1H-indol-3-yl)butyl]-1-piperazinyl}-1-benzofuran-2-carboxamide
2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]- Viibryd 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide 5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide 5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide vilazodone |
Description | Vilazodone (EMD 68843; SB 659746A) is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evaluation for the treatment of major depression.IC50 value:Target: SSRI; 5-HT1AVilazodone represents another option for the treatment of MDD. Vilazodone appears to have a favourable weight-gain profile based on short-term studies. Sexual side-effects were not consistently demonstrated when assessed using clinical rating scales but spontaneously reported AEs related to sexual functioning were observed. Additional controlled data regarding long-term efficacy and effectiveness will help characterise this new agent when used in maintenance treatment. |
---|---|
Related Catalog | |
References |
Density | 1.34 g/cm3 |
---|---|
Boiling Point | 745.1ºC at 760 mmHg |
Melting Point | 203-205ºC |
Molecular Formula | C26H27N5O2 |
Molecular Weight | 441.52 |
PSA | 102.29000 |
LogP | 5.53478 |
Storage condition | -20°C |